Clinical Features and Progress in Diagnosis and Treatment of Amyotrophic Lateral Sclerosis

Overview

Journal Ann Med

Publisher Informa Healthcare

Specialty General Medicine

Date 2024 Dec 3

PMID 39624969

Authors

Dongxiang Yuan

Shishi Jiang

Renshi Xu

Affiliations

Soon will be listed here.

Abstract

Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disease of the central nervous system. Despite a large number of studies, the current prognosis of ALS is still not ideal. This article briefly describes the clinical features including epidemiology, genetic structure and clinical manifestations, as well as the progress of new diagnostic criteria and treatment of ALS. Meanwhile, we also discussed further both developments and improvements to enhance understanding and accelerating the introduction of the effective treatments of ALS.

References

Babu S, Pioro E, Li J, Li Y . Optimizing muscle selection for electromyography in amyotrophic lateral sclerosis. Muscle Nerve. 2016; 56(1):36-44. DOI: 10.1002/mus.25444. View

Shi J, Qin X, Chang X, Wang H, Guo J, Zhang W . Neurofilament markers in serum and cerebrospinal fluid of patients with amyotrophic lateral sclerosis. J Cell Mol Med. 2021; 26(2):583-587. PMC: 8743649. DOI: 10.1111/jcmm.17100. View

Phukan J, Pender N, Hardiman O . Cognitive impairment in amyotrophic lateral sclerosis. Lancet Neurol. 2007; 6(11):994-1003. DOI: 10.1016/S1474-4422(07)70265-X. View

Brodovitch A, Boucraut J, Delmont E, Parlanti A, Grapperon A, Attarian S . Combination of serum and CSF neurofilament-light and neuroinflammatory biomarkers to evaluate ALS. Sci Rep. 2021; 11(1):703. PMC: 7803734. DOI: 10.1038/s41598-020-80370-6. View

Beeldman E, Govaarts R, de Visser M, Klein Twennaar M, van der Kooi A, van den Berg L . Progression of cognitive and behavioural impairment in early amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry. 2020; 91(7):779-780. PMC: 7361007. DOI: 10.1136/jnnp-2020-322992. View

Lu L, Deng Y, Xu R . Current potential therapeutics of amyotrophic lateral sclerosis. Front Neurol. 2024; 15:1402962. PMC: 11076685. DOI: 10.3389/fneur.2024.1402962. View

Salamone P, Fuda G, Casale F, Marrali G, Lunetta C, Caponnetto C . G-CSF (filgrastim) treatment for amyotrophic lateral sclerosis: protocol for a phase II randomised, double-blind, placebo-controlled, parallel group, multicentre clinical study (STEMALS-II trial). BMJ Open. 2020; 10(3):e034049. PMC: 7202695. DOI: 10.1136/bmjopen-2019-034049. View

Feldman E, Goutman S, Petri S, Mazzini L, Savelieff M, Shaw P . Amyotrophic lateral sclerosis. Lancet. 2022; 400(10360):1363-1380. PMC: 10089700. DOI: 10.1016/S0140-6736(22)01272-7. View

Walhout R, Verstraete E, van den Heuvel M, Veldink J, van den Berg L . Patterns of symptom development in patients with motor neuron disease. Amyotroph Lateral Scler Frontotemporal Degener. 2017; 19(1-2):21-28. DOI: 10.1080/21678421.2017.1386688. View

10.

Carvalho T, de Almeida L, Lorega C, Barata M, Brito Ferreira M, de Brito-Marques P . Depression and anxiety in individuals with amyotrophic lateral sclerosis: a systematic review. Trends Psychiatry Psychother. 2016; 38(1):1-5. DOI: 10.1590/2237-6089-2015-0030. View

11.

Saracino D, Dorgham K, Camuzat A, Rinaldi D, Rametti-Lacroux A, Houot M . Plasma NfL levels and longitudinal change rates in and -associated diseases: from tailored references to clinical applications. J Neurol Neurosurg Psychiatry. 2021; 92(12):1278-1288. PMC: 8606463. DOI: 10.1136/jnnp-2021-326914. View

12.

Shayya L, Babu S, Pioro E, Li J, Li Y . Distal Predominance of Electrodiagnostic Abnormalities in Early-Stage Amyotrophic Lateral Sclerosis. Muscle Nerve. 2018; 58(3):389-395. DOI: 10.1002/mus.26158. View

13.

Li C, Ou R, Wei Q, Shang H . Shared genetic links between amyotrophic lateral sclerosis and obesity-related traits: a genome-wide association study. Neurobiol Aging. 2021; 102:211.e1-211.e9. DOI: 10.1016/j.neurobiolaging.2021.01.023. View

14.

Bresch S, Delmont E, Soriani M, Desnuelle C . [Electrodiagnostic criteria for early diagnosis of bulbar-onset ALS: a comparison of El Escorial, revised El Escorial and Awaji algorithm]. Rev Neurol (Paris). 2013; 170(2):134-9. DOI: 10.1016/j.neurol.2013.10.004. View

15.

Gawel M, Kuzma-Kozakiewicz M, Szmidt-Salkowska E, Kaminska A . Are we really closer to improving the diagnostic sensitivity in ALS patients with Awaji criteria?. Amyotroph Lateral Scler Frontotemporal Degener. 2014; 15(3-4):257-61. DOI: 10.3109/21678421.2014.887118. View

16.

Chio A, Mora G, Lauria G . Pain in amyotrophic lateral sclerosis. Lancet Neurol. 2016; 16(2):144-157. DOI: 10.1016/S1474-4422(16)30358-1. View

17.

Donini L, Tanel R, Zuccarino R, Basso M . Protein biomarkers for the diagnosis and prognosis of Amyotrophic Lateral Sclerosis. Neurosci Res. 2023; 197:31-41. DOI: 10.1016/j.neures.2023.09.002. View

18.

Goutman S, Hardiman O, Al-Chalabi A, Chio A, Savelieff M, Kiernan M . Emerging insights into the complex genetics and pathophysiology of amyotrophic lateral sclerosis. Lancet Neurol. 2022; 21(5):465-479. PMC: 9513754. DOI: 10.1016/S1474-4422(21)00414-2. View

19.

Camu W, Mickunas M, Veyrune J, Payan C, Garlanda C, Locati M . Repeated 5-day cycles of low dose aldesleukin in amyotrophic lateral sclerosis (IMODALS): A phase 2a randomised, double-blind, placebo-controlled trial. EBioMedicine. 2020; 59:102844. PMC: 7502670. DOI: 10.1016/j.ebiom.2020.102844. View

20.

Vucic S, Kiernan M . Transcranial Magnetic Stimulation for the Assessment of Neurodegenerative Disease. Neurotherapeutics. 2016; 14(1):91-106. PMC: 5233629. DOI: 10.1007/s13311-016-0487-6. View